Apeloa Pharmaceutical Co Ltd (000739) — Cash Flow-to-Debt Ratio
Apeloa Pharmaceutical Co Ltd (000739) has a Cash Flow-to-Debt Ratio of 0.07x as of December 2025, meaning its operating cash flow of CN¥446.18 Million could theoretically repay 0% of its total liabilities (CN¥5.97 Billion) in one year. See 000739 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apeloa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Apeloa Pharmaceutical Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see 000739 operating cash flow.
Annual Cash Flow-to-Debt Ratio for Apeloa Pharmaceutical Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Apeloa Pharmaceutical Co Ltd. Check Apeloa Pharmaceutical Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.21x | CN¥1.23 Billion | CN¥5.97 Billion | ▲ +1.9% |
| 2024 | 0.20x | CN¥1.21 Billion | CN¥5.98 Billion | ▲ +28.1% |
| 2023 | 0.16x | CN¥1.03 Billion | CN¥6.54 Billion | ▼ -22.6% |
| 2022 | 0.20x | CN¥1.33 Billion | CN¥6.50 Billion | ▲ +32.8% |
| 2021 | 0.15x | CN¥611.75 Million | CN¥3.98 Billion | ▼ -55.0% |
| 2020 | 0.34x | CN¥1.06 Billion | CN¥3.10 Billion | ▼ -30.9% |
| 2019 | 0.49x | CN¥1.36 Billion | CN¥2.75 Billion | ▲ +42.7% |
| 2018 | 0.35x | CN¥832.69 Million | CN¥2.41 Billion | ▲ +335.6% |
| 2017 | 0.08x | CN¥209.80 Million | CN¥2.64 Billion | ▲ +32.2% |
| 2016 | 0.06x | CN¥180.42 Million | CN¥3.00 Billion | ▼ -59.4% |
| 2015 | 0.15x | CN¥441.16 Million | CN¥2.98 Billion | ▼ -48.1% |
| 2014 | 0.29x | CN¥786.64 Million | CN¥2.76 Billion | ▲ +320.3% |
| 2013 | 0.07x | CN¥190.45 Million | CN¥2.80 Billion | ▼ -44.6% |
| 2012 | 0.12x | CN¥335.90 Million | CN¥2.74 Billion | ▼ -27.5% |
| 2011 | 0.17x | CN¥404.62 Million | CN¥2.40 Billion | ▲ +44.6% |
| 2010 | 0.12x | CN¥121.05 Million | CN¥1.04 Billion | ▼ -46.4% |
| 2009 | 0.22x | CN¥208.30 Million | CN¥954.91 Million | ▲ +124.4% |
| 2008 | 0.10x | CN¥94.57 Million | CN¥973.00 Million | ▼ -51.8% |
| 2007 | 0.20x | CN¥174.20 Million | CN¥864.02 Million | ▲ +4.8% |
| 2006 | 0.19x | CN¥159.43 Million | CN¥828.68 Million | ▲ +61.3% |
| 2005 | 0.12x | CN¥87.40 Million | CN¥732.94 Million | ▲ +86.4% |
| 2004 | 0.06x | CN¥47.54 Million | CN¥743.40 Million | ▼ -67.6% |
| 2003 | 0.20x | CN¥105.36 Million | CN¥534.24 Million | ▲ +2672.0% |
| 2002 | 0.01x | CN¥2.81 Million | CN¥395.59 Million | ▲ +509.1% |
| 2001 | 0.00x | CN¥-569.79K | CN¥327.67 Million | ▼ -104.4% |
| 2000 | 0.04x | CN¥7.08 Million | CN¥177.79 Million | ▲ +141.2% |
| 1999 | -0.10x | CN¥-20.52 Million | CN¥212.40 Million | ▼ -172.9% |
| 1998 | 0.13x | CN¥30.10 Million | CN¥227.17 Million | — |